By Daily Mail (U.S.) | Created at 2026-07-29 23:02:42 | Updated at 2026-07-30 00:22:36
1 hour ago
GLP-1 weight-loss drugs have transformed the way millions of Americans lose weight, but as their use reaches record levels, doctors say they're seeing a worrying new trend emerge.
Rather than sticking with one medication, some patients are repeatedly switching between drugs, such as Wegovy, Mounjaro and Ozempic, hoping to lose weight faster, escape unpleasant side effects or simply gain access to whichever drug is available.
Experts warn that treating the blockbuster injections like a revolving door can backfire, potentially worsening side effects, disrupting treatment and making it harder to achieve lasting weight loss.
'We're seeing far more patients asking to switch between GLP-1 medications,' Dr Carol Eisenstat, founder and medical director of Line Eraser MD, told the Daily Mail.
'Sometimes it's because of side effects, sometimes insurance changes, sometimes the medication just isn't giving them the results they expected. Switching itself isn't dangerous, but it shouldn't be done casually.'
But on social media, patients swap recommendations and dramatic before-and-after photos that can create the impression that one drug is universally 'better' than another.
'The biggest mistake I see is people "GLP-1 hopping" because they've heard someone else lost more weight on a different medication,' Dr Eisenstat said.
'Weight loss isn't one-size-fits-all. The medication that's best for your spouse, friend or colleague may not be the best one for you.'
GLP-1 use is more prevalent than ever, but some are starting to treat the drugs like a revolving door
Use of the drugs continues to surge, with a recent Gallup poll finding that 11 percent of US adults now take a GLP-1 medication, up from three percent in 2024.
But while Ozempic, Wegovy, Mounjaro and Zepbound are all popular injectable medications used to treat obesity or diabetes, they are not interchangeable.
'They work slightly differently, are prescribed on different dosing schedules and can produce different side-effect profiles,' Dr Eisenstat told the Daily Mail.
'You can't assume that because you were fine on one, you'll not suffer side effects another. That's one of the biggest misconceptions I try to dispel in my practice.'
Wegovy and Ozempic both contain semaglutide, while Mounjaro and Zepbound contain tirzepatide. And while tirzepatide and semaglutide may be grouped together as 'GLP-1 drugs,' they are not interchangeable.
Unlike semaglutide, tirzepatide acts on two hormone receptors – GLP-1 and GIP – rather than GLP-1 alone, which is one reason the drugs can differ in their effectiveness and side effects.
'Because tirzepatide works on two pathways, it produces stronger effects on appetite and insulin response and often more weight loss,' said Tarun Kumar, co-founder and superintendent pharmacist at Cured Pharmacy.
'There is no validated dose equivalence between semaglutide and tirzepatide,' Kumar added.
'The safest approach is to start the new medication at its lowest recommended dose and gradually increase it according to the standard schedule.'
Failing to do so can increase the risk of side effects.
'Both drugs remain in the body for around a week after the last injection,' Kumar explained. 'If they overlap, side effects can be amplified. Skipping the low-dose titration of the new drug also raises the risk of nausea, vomiting and dehydration.'
In more serious cases, patients may also face an increased risk of complications including pancreatitis – inflammation of the pancreas that can require hospitalization – and gallbladder disease, which can cause severe abdominal pain and may require surgery.
That's why, he says, patients should never switch medications without medical supervision. A doctor can advise how long you need to wait for the first medication to leave your system before starting the next one – known as a washout period – and recommend the safest starting dose.
The process becomes even more complicated when patients switch from FDA-approved GLP-1 medications to compounded versions – custom-made drugs prepared by specialist pharmacies.
Unlike the licensed brand-name medications, compounded GLP-1 drugs can vary depending on how they're prepared and which pharmacy makes them, meaning dosing may not always be directly comparable.
'If you're changing products, you want to make sure you're working with a provider who understands the differences in dosing and is monitoring you appropriately,' Dr Eisenstat said.
Some patients have been hopping from drug, switching rapidly from Wegovy to Mounjaro and back to Ozempic
She said that should include regular blood tests, weight checks and monitoring of skeletal muscle mass.
Dr Eisenstat stressed that compounded GLP-1 medications are not inherently unsafe – something she describes as a common misconception – but said patients should understand exactly where their medication comes from.
'Ask where your medication is made. Ask whether it's independently tested. Ask why your provider chose that pharmacy. If they can't answer those questions in detail, that's a red flag,' she said.
Kumar agreed, adding that poor quality control can make switching even more difficult.
'If a compounded product hasn't been properly tested, it's impossible to know exactly what dose a patient is switching from,' he said. 'That makes starting low and increasing gradually even more important.'
Ultimately, Dr Eisenstat says patients shouldn't fall into the trap of constantly searching for a 'better' GLP-1.
'The goal isn't to keep chasing the next medication,' she said.
'The goal is to find the one your body responds well to and stay consistent. That's where I see the best long-term outcomes.'
